Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis

NCT01707264 is registered in ClinicalTrials.gov with Prothena Biosciences Ltd. as lead sponsor.

NCT NCT01707264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01707264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Lead sponsor
Prothena Biosciences Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2013
Completion date
August 9, 2016
Enrollment
69 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

primary amyloidosis